Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II trial assessing Middle East respiratory syndrome coronavirus vaccine

Trial Profile

A phase II trial assessing Middle East respiratory syndrome coronavirus vaccine

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 06 Jan 2020

At a glance

  • Drugs GLS 5300 (Primary)
  • Indications Middle East respiratory syndrome coronavirus
  • Focus Therapeutic Use
  • Sponsors Inovio Pharmaceuticals
  • Most Recent Events

    • 06 Jan 2020 According to an Inovio Pharmaceuticals media release, the company expects to initiate this trial in 2020.
    • 25 Jul 2019 According to an Inovio Pharmaceuticals media release, the company is planning this trial based on the data of previous Phase 1b/2a trial(CTP 700288728).
    • 18 Mar 2019 New trial record

Trial Overview

Purpose

This study will evaluate the Middle East respiratory syndrome coronavirus vaccine for the prevention of Middle East respiratory syndrome.

Diseases Treated

Indication Qualifiers Patient Segments
Middle East respiratory syndrome coronavirus prevention -

Subjects

  • Subject Type patients
  • Sex male & female

Patient Inclusion Criteria

Patients with Middle East respiratory syndrome.

Trial Details

Organisations

  • Sponsors Inovio Pharmaceuticals
  • Affiliations Inovio Pharmaceuticals

Trial Dates

Other Details

  • Design multicentre; prospective
  • Phase of Trial Phase II
  • Location Middle East
  • Focus Therapeutic Use

Interventions

Drugs Route Formulation
GLS 5300Primary Drug Intradermal
-

Middle East respiratory syndrome coronavirus vaccine

Trial Centres

Centres

Centre Name Location Trial Centre Country
Inovio Pharmaceuticals
-
-

Trial History

Event Date Event Type Comment
06 Jan 2020 Other trial event According to an Inovio Pharmaceuticals media release, the company expects to initiate this trial in 2020. Updated 07 Jan 2020
25 Jul 2019 Other trial event According to an Inovio Pharmaceuticals media release, the company is planning this trial based on the data of previous Phase 1b/2a trial(CTP 700288728). Updated 29 Jul 2019
18 Mar 2019 New trial record New trial record Updated 18 Mar 2019
12 Mar 2019 Other trial event According to a Inovio Pharmaceuticals media release, this trial is expected to commence in the second half of 2019. Updated 18 Mar 2019
05 Sep 2018 Other trial event According to a Inovio Pharmaceuticals media release, CEPI will be funding this trial. This trial is expected to commence in 2019. Updated 18 Mar 2019

References

  1. Inovio Pharmaceuticals. Inovio Doses 1st Subject in Phase 1/2 Clinical Trial For Vaccine Against Deadly MERS Infection. Media-Rel 2018;.

    Media Release
  2. Inovio Pharmaceuticals. Inovio Pharmaceuticals Reports 2018 Fourth Quarter and Year-End Financial Results. Media-Rel 2019;.

    Media Release
  3. Inovio Pharmaceuticals. Inovio's Positive First-in-Human MERS Vaccine Results Published in The Lancet Infectious Diseases. Media-Rel 2019;.

    Media Release
  4. Inovio Pharmaceuticals. Inovio Provides Update on Clinical Program Plans for 2020. Media-Rel 2020;.

    Media Release
Back to top